


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+9.65%
-1.15%
-16.03%
+3.58%
-16.49%
ROIV
Roivant Sciences Ltd.
$27.67
Strengths

Upgraded on attractively valued

Outperform the market
ROIV Price Performance
$21.98 (+25.89%)
$20.9 (+32.39%)
$13.95 (+98.35%)
$10.52 (+163.02%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Outperform the market
Analysts perspectives on the stock desirability, trend direction and growth potential
ROIV has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Dec 16, 2025
Reiterate
Outperform
Leerink
Nov 12, 2025
Reiterate
Buy
Citigroup
What is ROIV current stock price?
What are ROIV stock strengths?
What is ROIV Risk Level?
What is ROIV market cap and volume?
What is ROIV current Stock IQ?
Should I buy ROIV stock right now?
Is ROIV a Strong Buy right now?
What does a 'Strong Buy' rating mean for ROIV?
What does a 'Strong Sell' rating mean for ROIV?
What factors influence ROIV's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.65%
-1.15%
-16.03%
+3.58%
-16.49%
ROIV
Roivant Sciences Ltd.
Current Price
$27.67

ROIV Price Performance
$21.98 (+25.89%)
$20.9 (+32.39%)
$13.95 (+98.35%)
$10.52 (+163.02%)
ROIV Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Outperform the market
Analysts perspectives on the stock desirability, trend direction and growth potential
ROIV has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Dec 16, 2025
Reiterate
Outperform
Leerink
Nov 12, 2025
Reiterate
Buy
Citigroup
ROIV Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Outperform the market
ROIV Latest Analysis
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss Misses Revenue Estimates. Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 9.43% and -67.32% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Fri Feb 6, 2026
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib . (RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous sarcoidosis.
Fri Feb 6, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ROIV Stock trends
ROIV Stock performance
ROIV Stock analysis
ROIV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.